• ARS Pharmaceuticals posted Q1 net loss of USD 60.62 million, widening 79% from year-earlier period as revenue more than doubled to USD 22.68 million.
• Product revenue, net climbed 125% to USD 17.45 million; revenue under collaboration agreements rose to USD 2.49 million.
• Operating loss widened 62% to USD 60.15 million, while selling, general and administrative expense increased 76% to USD 72.2 million.
• Commercial launch metrics showed about 120,000 patients using neffy in the U.S. at quarter-end, with about 29,500 added during the quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-225142), on May 15, 2026, and is solely responsible for the information contained therein.